Led by former Sarepta CEO, antisense startup Stoke Therapeutics has raked in $90 million in series B financing, following up the $40 million announced earlier this year.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,